Department of Pathology
Brigham and Women's Hospital
A teaching Affliate of Harvard Medical School
 

Name and Present Position:

WILLIAM R. WELCH, Pathologist

Address:

Brigham and Women's Hospital, Department of Pathology, 75 Francis Street, Boston, MA

Medical School (including school name, date and degree awarded):

1971 MD, Duke University School of Medicine, Durham, NC
  Graduate Medical Education (including dates and institution of internship, residencies, fellowships, etc.):

1971-1972 Intern in Anatomic Pathology, Upstate Medical Center, Syracuse, NY
1972-1974 Resident in Anatomic and Clinical Pathology, Upstate Medical Center
1974-1975 Resident in Anatomic Pathology, New England Deaconess Hospital, Boston, MA;
Clinical Fellow in Pathology, American Cancer Society
1976-1979 Junior Faculty Clinical Fellow (Gyn. Pathology), American Cancer Society, Massachusetts General Hospital, Boston, MA

Certification:

1975 American Board of Pathology (Anatomic and Clinical Pathology)

Current Academic Appointment:

Associate Professor of Pathology, Harvard Medical School, Boston, MA

Current Medical Staff Appointment:

Pathologist, Brigham and Women's Hospital

Selected Bibliography:

  • Poteat HT, Ho GT, Lee MLT, Welch WR, Loughlin K, Sacks DB. The utility of patient age in evaluating prostate cancer. Am J Clin Pathol 1997; 107:337-344.
  • Edelson MI, Scherer SW, Tsui LC, Welch WR, Bell DA, Berkowitz RS, Mok SC. Identification of a 1300 Kilobase deletion unit on chromosome 7q31.3 in invasive epithelial ovarian carcinomas. Oncogene 1997; 14:2979-2984.
  • Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over the counter analgesics and risk of ovarian cancer. Lancet 1998; 351:104-107.
  • Lu KH, Bell DA, Welch WR, Berkowitz RS, Mok SC. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 1998; 58:2328-2330.
  • Schorge JO, Muto MG, Welch WR, Bandera CA, Rubin SC, Bell DA, Berkowitz RS, Mok SC. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 1998; 90:841-845.